175 related articles for article (PubMed ID: 35853850)
1. Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study.
Pagano L; Criscuolo M; Broccoli A; Piciocchi A; Varettoni M; Galli E; Anastasia A; Cantonetti M; Trentin L; Kovalchuk S; Orsucci L; Frustaci A; Spolzino A; Volpetti S; Annibali O; Storti S; Stelitano C; Marchesi F; Offidani M; Casadei B; Nizzoli ME; De Luca ML; Fianchi L; Motta M; Guarnera L; Simonetti E; Visentin A; Vassallo F; Deodato M; Sarlo C; Olivieri A; Falini B; Pulsoni A; Tiacci E; Zinzani PL
Blood Cancer J; 2022 Jul; 12(7):109. PubMed ID: 35853850
[TBL] [Abstract][Full Text] [Related]
2. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
Goodman GR; Burian C; Koziol JA; Saven A
J Clin Oncol; 2003 Mar; 21(5):891-6. PubMed ID: 12610190
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of 34 cases of hairy cell leukemia treated with interferon-alpha and/or 2-chlorodeoxyadenosine.
Zaja F; Fanin R; Silvestri F; Russo D; Infanti L; Baccarani M
Haematologica; 1997; 82(4):468-70. PubMed ID: 9299866
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
Madanat YF; Rybicki L; Radivoyevitch T; Jagadeesh D; Dean R; Pohlman B; Kalaycio M; Sekeres MA; Smith MR; Hill BT
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):857-862. PubMed ID: 28778620
[TBL] [Abstract][Full Text] [Related]
5. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
6. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
[TBL] [Abstract][Full Text] [Related]
7. [Clinical analysis of 24 patients of hairy cell leukemia treated by cladribine].
Wang TY; Li ZJ; Lyu R; Fu MW; Sui WW; Huang WY; Liu W; An G; Deng SH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):491-495. PubMed ID: 30032567
[No Abstract] [Full Text] [Related]
8. Long-term follow-up of patients with hairy cell leukemia in the south of Iran.
Dehghani M; Kashkooe A; Namdari N; Majidi R; Karimi M; Haghighat S; Rezvani A; Safari N
Expert Rev Hematol; 2023 Apr; 16(4):289-295. PubMed ID: 36709461
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series.
Rosenberg JD; Burian C; Waalen J; Saven A
Blood; 2014 Jan; 123(2):177-83. PubMed ID: 24192579
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.
Hoffman MA; Janson D; Rose E; Rai KR
J Clin Oncol; 1997 Mar; 15(3):1138-42. PubMed ID: 9060556
[TBL] [Abstract][Full Text] [Related]
11. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant].
Wei C; Jin XX; Cai H; Wang X; Zhuang JL; Zhou DB
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):416-421. PubMed ID: 37032137
[No Abstract] [Full Text] [Related]
13. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine.
Dearden CE; Matutes E; Hilditch BL; Swansbury GJ; Catovsky D
Br J Haematol; 1999 Aug; 106(2):515-9. PubMed ID: 10460614
[TBL] [Abstract][Full Text] [Related]
14. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
Else M; Dearden CE; Matutes E; Garcia-Talavera J; Rohatiner AZ; Johnson SA; O'Connor NT; Haynes A; Osuji N; Forconi F; Lauria F; Catovsky D
Br J Haematol; 2009 Jun; 145(6):733-40. PubMed ID: 19344416
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.
Saven A; Burian C; Koziol JA; Piro LD
Blood; 1998 Sep; 92(6):1918-26. PubMed ID: 9731048
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review.
Néel A; Artifoni M; Fontenoy AM; Tessoulin B; Lorillon G; Cohen-Aubart F; Haroche J; Genereau T; de Menthon M; Guillevin L; Maillard H; Kahn JE; Hermine O; Araujo C; Dromer C; Jullien D; Hamidou M; Donadieu J; Tazi A
Br J Haematol; 2020 Jun; 189(5):869-878. PubMed ID: 32191819
[TBL] [Abstract][Full Text] [Related]
19. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up.
Paillassa J; Cornet E; Noel S; Tomowiak C; Lepretre S; Vaudaux S; Dupuis J; Devidas A; Joly B; Petitdidier-Lionnet C; Haiat S; Mariette C; Thieblemont C; Decaudin D; Validire-Charpy P; Drenou B; Eisenmann JC; Uribe MO; Olivrie A; Touati M; Lambotte O; Hermine O; Karsenti JM; Feugier P; Vaillant W; Gutnecht J; Lippert E; Huysman F; Ghomari K; Boubaya M; Levy V; Riou J; Damaj G; Tanguy-Schmidt A; Hunault-Berger M; Troussard X
Blood Cancer J; 2020 May; 10(5):62. PubMed ID: 32461544
[TBL] [Abstract][Full Text] [Related]
20. The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience.
Broccoli A; Argnani L; Nanni L; Terragna C; Sabattini E; Gabrielli G; Stefoni V; Pellegrini C; Casadei B; Morigi A; Lolli G; Carella M; Coppola PE; Zinzani PL
Am J Hematol; 2021 Oct; 96(10):1204-1210. PubMed ID: 34245477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
